Aspirin study
This article was originally published in The Tan Sheet
Executive Summary
Peter Gann, MD, Northwestern University Medical School, et al., concluded that "regular aspirin use, at a dose adequate for preventing myocardial infarction, was not associated with a substantial reduction in the incidence of colorectal cancer during five years of randomized treatment and follow-up." Published in the Aug. 4 Journal of the National Cancer Institute, the study also inferred that low-dose aspirin users are not likely to have an increased incidence of colorectal cancer due to aspirin-induced G-I bleeding. However, Gann et al. recommended that additional epidemiologic studies and prevention trials be undertaken to assess the potential benefits of higher doses of aspirin or a longer duration of use.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning